

ICLUSIG[®] FILM-COATED TABLETS

Ponatinib (15 mg and 45 mg)

What is in this leaflet

1. What Iclusig is used for
2. How Iclusig works
3. Before you use Iclusig
4. How to use Iclusig
5. While you are using it
6. Side effects
7. Storage and Disposal of Iclusig
8. Product Description
9. Manufacturer and Product Registration Holder
10. Date of Revision
11. Serial number

Please refer to the Patient Medication Guide that comes with Iclusig before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. If you have any questions about Iclusig, ask your healthcare provider.

What Iclusig is used for

Iclusig is used to treat adults with the following leukaemia types who are no longer benefiting from treatment with other medicines, or have a certain genetic difference known as a T315I mutation:

- *Chronic myeloid leukaemia* (CML): a blood cancer involving too many abnormal white blood cells in the blood and the bone marrow (where blood cells are formed).
- *Philadelphia-chromosome* positive acute lymphoblastic leukaemia (Ph+ ALL): a type of leukaemia involving too many immature white blood cells in the blood and blood forming bone marrow. In this kind of leukaemia, some of the DNA (genetic material) has
- rearranged to form an abnormal chromosome, the Philadelphia chromosome.

[Iclusig, in combination with chemotherapy, is also used to treat](#)

[adults with newly diagnosed Ph+ ALL.](#)

How Iclusig works

Iclusig belongs to a group of medicines called tyrosine kinase inhibitors. In patients with CML and Ph+ ALL, changes in the DNA trigger a signal that tells the body to produce abnormal white blood cells. Iclusig blocks this signal, thereby stopping the production of these cells.

Before you use Iclusig

When you must not use it

Do not take Iclusig if you are allergic to ponatinib or any of the other ingredients of this medicine. See the end of this leaflet for a list of ingredients in Iclusig.

Before you start to use it

Talk to your doctor before taking Iclusig if you have:

- A liver or pancreas disorder or reduced kidney function. Your doctor may want to take additional precautions
- A history of alcohol abuse
- Had a prior heart attack or stroke
- A history of blood clots in your blood vessels
- A history of renal artery stenosis (narrowing of the blood vessels to one or both kidneys)
- Heart problems, including heart failure, irregular heartbeats, and QT prolongation
- High blood pressure
- Had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall
- A history of bleeding issues
- Ever had or might now have a hepatitis B infection. This is because Iclusig could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started

Your doctor will perform:

- Evaluations of your heart function and the condition of your arteries and veins

- A complete blood count

This will be repeated every 2 weeks for the first 3 months after starting the therapy. Afterwards it is performed monthly or as indicated by the doctor.

- Checks of the serum protein known as lipase

A serum protein called lipase will be checked every 2 weeks for the first 2 months, then periodically. A break in treatment or a decrease in dose may be required when lipase is increased.

- Liver function tests will be performed periodically, as indicated by your doctor.

A brain condition called posterior reversible encephalopathy syndrome (PRES) has been reported in patients treated with ponatinib. Symptoms may include sudden onset of severe headache, confusion, seizures, and vision changes. Tell your doctor straight away if you experience any of these symptoms during your treatment with ponatinib, because it could be serious.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

- Women of childbearing age being treated with Iclusig should avoid becoming pregnant.
- Men receiving treatment with Iclusig are advised not to father a child during treatment. Effective contraception must be used during treatment.
- Only use Iclusig during pregnancy if your doctor tells you it is absolutely necessary, as potential risks exist for the unborn child.
- Stop breast-feeding during treatment with Iclusig. It is not known if Iclusig passes into breast milk.

Taking other medicines

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. The following medicines can affect or be affected by Iclusig:

- **ketoconazole, itraconazole, voriconazole:** medicines to treat fungal infections.
- **indinavir, nelfinavir, ritonavir, saquinavir:** medicines to treat HIV infection.
- **clarithromycin, telithromycin, troleandomycin:** medicines to treat bacterial infections.
- **nefazodone:** a medicine to treat depression.
- **St. John's wort:** a herbal product used to treat depression.
- **carbamazepine:** a medicine to treat epilepsy, euphoric/depressive stages and certain pain conditions.
- **phenobarbital, phenytoin:** medicines to treat epilepsy.
- **rifabutin, rifampicin:** medicines to treat tuberculosis or certain other infections.
- **digoxin:** a medicine to treat heart weakness.
- **dabigatran:** a medicine to prevent the formation of blood clots.
- **colchicine:** a medicine to treat gout attacks.
- **pravastatin, rosuvastatin:** medicines to lower elevated cholesterol levels.
- **methotrexate:** a medicine to treat severe joint inflammation (rheumatoid arthritis), cancer and the skin disease psoriasis.
- **sulfasalazine:** a medicine to treat severe bowel and rheumatic joint inflammation.

How to use Iclusig

Iclusig should be prescribed by a doctor experienced in leukaemia treatment.

How much to use

Adults with CML and Ph+ ALL who are no longer benefiting from treatment with other medicines, or have T315I mutation.

The recommended starting dose is one 45 mg film-coated tablet once daily.

Adults with newly diagnosed Ph+ ALL in combination with chemotherapy.

The recommended starting dose is two 15 mg film-coated tablets i.e., 30 mg once daily.

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Your doctor may reduce your dose or tell you to temporarily stop taking Iclusig if:

- an appropriate response to the treatment is reached
- The number of white blood cells called neutrophils is reduced
- The number of blood platelets is reduced
- A severe side effect occurs, not affecting the blood, such as:
 - Pancreas inflammation
 - Increased levels of the serum proteins lipase or amylase
- You develop heart or blood vessel problems
- You have a liver disorder

Iclusig use may be resumed at the same, or a reduced dose, after the event is resolved or controlled. Your doctor may evaluate your response to the treatment at regular intervals.

When to use it

Swallow the tablets whole, with a glass of water. The tablets can be taken with or without food. Do not crush or dissolve the tablets.

Do not swallow the desiccant canister contained in the bottle.

How long to use it

Make sure you take Iclusig daily for as long as it is prescribed. This is a long-term treatment.

If you forget to use it

Do not take a double dose to make up for a forgotten dose. Take your next dose at your regular time.

If you use too much (overdose)

Talk to your doctor immediately if this occurs.

While you are using it

Things you must do

- Avoid grapefruit products such as grapefruit juice.

Things you must not do

- Do not stop taking Iclusig without your doctor's permission. If you have any further questions on the use of this medicine, ask your doctor.

Things to be careful of

- You should take special care when driving and using machines as patients taking Iclusig may experience visual disturbance, dizziness, sleepiness, and tiredness.

Side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Patients aged 65 and over are more likely to be affected by side effects.

Seek medical attention immediately if you experience any of the following **serious side effects**. If abnormal results from blood tests are received, a doctor should be contacted immediately.

Serious side effects (common: may affect up to 1 in 10 people):

- Lung infection (may cause breathing difficulty)
- Pancreas inflammation. Inform your doctor immediately if pancreas inflammation occurs. Symptoms are severe pain in the stomach and back
- Fever, often with other signs of infection due to decreased number of white blood cells
- Heart attack (symptoms include: sudden feeling of increased heart rate, chest pain, breathlessness)
- Changes in blood levels e.g.
 - decreased number of red blood cells (symptoms include: weakness, dizziness, fatigue)
 - decreased number of blood platelets (symptoms include: increased tendency to bleed or bruise)
 - decreased number of white blood cells called neutrophils (symptoms include: increase tendency of infection)
 - increased level of the serum protein known as lipase

Commented [M3]: This is added to provide differentiation on 'How much to use' between the current approved indications and proposed (new) indication.

Commented [M1]: This is added to provide differentiation on 'How much to use' between the current approved indications and proposed (new) indication.

- A heart rhythm disorder, abnormal pulse - Heart failure (symptoms include: weakness, fatigue, swollen legs) - Uncomfortable pressure, fullness, squeezing or pain in the centre of the chest (Angina pectoris) and chest pain not in connection with the heart - High blood pressure - Narrowing of the arteries in the brain - Problems of the blood vessels in the heart muscle - Blood infection - Swollen, or red area of skin that feels hot and tender (cellulitis) - Dehydration - Breathing difficulties - Fluid in the thorax (may cause breathing difficulty) - Diarrhoea - Blood clot in a deep vein, sudden vein obstruction, blood clot in a blood vessel of the lung (symptoms include: hot flush, flushing, redness of the face, breathing difficulty) - Stroke (symptoms include: difficulty to speak or move, sleepiness, migraine, abnormal sensations) - Blood circulation problems (symptoms include: pain in the legs or arms, coldness of the extremities of the limbs) - Blood clot in the main arteries carrying blood to the head or neck (carotid artery) - Constipation - Sodium decrease in the blood - Increased tendency to bleed or bruise	- Rash, dry skin, itching - Pain in bones, joints, pain in muscles, back, arms or legs, muscle spasms - Fatigue, accumulation of fluid in arms and/or legs, fever, pain	Do not use this medicine after the expiry date which is stated on the bottle label and carton after EXP. The expiry date refers to the last day of that month.
Other possible side effects that may occur with the following frequencies are:	<u>Adults with newly diagnosed Ph+ ALL, in combination with chemotherapy:</u>	Store in the original container in order to protect from light. Store at or below 30°C.
Very common side effects (may affect more than 1 in 10 people): - Upper airway infection (may cause breathing difficulty) - Decreased appetite - Insomnia - Headache, dizziness - Cough - Diarrhoea, vomiting, nausea - Increased levels of several liver enzymes called: - alanine aminotransferase - aspartate aminotransferase	<u>The most common side effects of Iclusig when given with chemotherapy include:</u> - <u>Liver problems</u> - <u>Joint pain</u> - <u>Skin rash</u> - <u>Headache</u> - <u>Fever</u> - <u>Stomach-area (abdomen) pain</u> - <u>Constipation</u> - <u>Tiredness</u> - <u>Nausea</u> - <u>Mouth sores</u> - <u>Increase in lipase levels (a blood test done to check your pancreas)</u> - <u>Numbness or tingling (pins and needles), pain, or weakness in the hands or feet</u> - <u>Fever due to low white blood cell counts (febrile neutropenia)</u> - <u>Swelling of your hands, ankles, feet, face, or all over your body (fluid retention and edema)</u> - <u>Vomiting</u> - <u>Irregular heartbeat</u> - <u>Low blood platelet counts</u> - <u>Low blood levels of white blood cells</u> - <u>Low haemoglobin in the blood (anaemia)</u> - <u>Changes in liver function tests</u> Not all side effects are listed in this leaflet. Please refer to the Patient Medication Guide for more detailed information on the side effects of Iclusig. If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You may report any side effects or adverse drug reactions directly to the National Centre for Adverse Drug Reaction Monitoring by visiting the website npra.gov.my [Consumers → Reporting Side Effects to Medicines (ConSERF) or Vaccines (AEFI)]. Storage and Disposal of Iclusig Storage Keep this medicine out of the sight and reach of children.	The bottle contains one sealed plastic canister containing a molecular sieve desiccant. Keep the canister in the bottle. Do not swallow the desiccant canister.
	Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.	Product Description
		What it looks like Iclusig tablets are white, round and rounded on the upper and lower side. Iclusig 15 mg film-coated tablets are approximately 6 mm in diameter with "A5" on one side. Iclusig 45 mg film-coated tablets are approximately 9 mm in diameter with "AP4" on one side.
		Iclusig is available in plastic bottles, each containing one canister of a molecular sieve desiccant. Bottles are packed within a cardboard box.
		Ingredients Active ingredient: ponatinib (as ponatinib hydrochloride) 15mg or 45mg Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, talc, polyethylene glycol, polyvinyl alcohol, titanium dioxide.
		MAL number Iclusig Film-Coated Tablet 15 mg (MAL19056102ACRZ) Iclusig Film-Coated Tablet 45 mg (MAL19056103ACRZ)
		Manufacturer: Takeda Ireland Limited Bray Business Park, Kilruddery, Wicklow, A98 CD36, Ireland

Commented [M4]: This is added to provide differentiation on the side effects between Iclusig when taken alone (current approved indications) and when taken in combination with chemotherapy (proposed indication).

Product Registration Holder:

Steward Cross Sdn Bhd
No. 2, Jalan SS13/5, 47500, Subang
Jaya, Selangor, Darul Ehsan

Date of revision

- [01 Jul 2025](#)~~27 Sep 2024~~
- Version: ~~4~~3

Serial number

[NPRA \(R1/AI2\) 16102025/017](#)
~~NPRA (R1/2) 20082024/157~~

Commented [M2]: Correspondence dated 16 Oct 2025
The RiMUP serial number has been updated as advised by the evaluator.